NRG-BR008 HERO / CRBRS23022 / Gergelis
Basic Study Information
Purpose:
This Phase III trial compares the recurrence-free interval (RFI) among patients with
early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and
receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy
versus those who are randomized to receive adjuvant radiotherapy per the standard
of care.
Location: Highland Hospital
Lead Researcher (Principal Investigator)
Lead Researcher:
Kimberly Gergelis
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search